Borje Andersson

Follow
Get notifications in MyBN when activity occurs.
Subscribe to BN Log In
Borje Andersson
Borje Andersson
Chief Medical Officer / Race Oncology

Professor Borje Andersson was initially engaged as a scientific and clinical consultant to Race Oncology in January 2019, before becoming chair of its clinical advisory board in December 2019 and chief medical officer in October 2020.

Prof Andersson is a research leader in the field of leukaemia and stem cell transplantation at the MD Anderson Cancer Center in Houston, Texas. He is the inventor of IV Busulfan, an FDA-approved drug used in stem cell transplantation.

Lists and Charts

Roles

2020
Chief Medical Officer
Race Oncology
Year started and most recent title

Total Shareholder Return as at 02/12/24

Rank Company 1 Yr 5 Yr
265th Objective Corporation">Objective Corporation 55.8% 25.08%
266th Metals X">Metals X 55.66% 29.82%
267th Race Oncology">Race Oncology 55.55% 49.18%
268th K&S Freighters">K&S Freighters 55.35% 24.09%
269th Aurelia Metals">Aurelia Metals 54.6% -15.33%
View Full List
1767 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

30/11/20
Issued
Race Oncology
30/11/20
Issued
Race Oncology
Total value as at the date of the transaction
Powered by Morningstar ®

      Person Activity

      Borje Andersson
      		NEW ROLE: Chief Medical Officer, Race Oncology 16 Apr 2021
      Borje Andersson
      		NEW ROLE: Executive Director, Race Oncology 03 Nov 2020

    Related Information

    Access to our data for Borje Andersson is only available to paid subscribers with Data & Insights access.

    Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

    Borje Andersson is linked to 2 organisations which are included in 1 list - Public Companies - non WA.

    To see the data you will need to Subscribe.

    X